Moreover, the IDH1(R132H)‐specific peptide vaccine (IDH1‐vac) elicited immune responses in 93.3% of patients diagnosed with WHO grade 3 and 4 IDH1(R132H) + astrocytomas, spanning multiple alleles.49 This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).